Annotation Detail
Information
- Associated Genes
- NTRK1
- Associated Variants
- NTRK1 LMNA-NTRK1
- Associated Disease
- colorectal adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- A gene fusion between exon 10 of NTRK1 and exon 11 of the LMNA genes was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-line irinotecan. The patient treated in a clinical trial with pan-TRK kinase inhibitor entrectinib. Treatment was well tolerated and led to a partial response (PR) with 30% tumor shrinkage of multiple liver metastases. Clinical response lasted 4 months.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2960
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3983
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1278
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Entrectinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26546295
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Entrectinib | Sensitivity | true |